DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0108693 A1 VERGEZ

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0108693 A1 VERGEZ US 2013 01 08693A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0108693 A1 VERGEZ. et al. (43) Pub. Date: May 2, 2013 (54) DUAL CONTROLLED RELEASE DOSAGE Publication Classification FORM (51) Int. Cl. (71) Applicants: Juan A. VERGEZ, Buenos Aires (AR): A619/00 (2006.01) Marcelo A. RICCI, Buenos Aires (AR) A619/24 (2006.01) 469/48 (2006.01) (72) Inventors: Juan A. VERGEZ, Buenos Aires (AR): A6II 45/06 (2006.01) Marcelo A. RICCI, Buenos Aires (AR) (52) U.S. Cl. CPC ............... A61 K9/0004 (2013.01); A61K 45/06 (2013.01); A61 K9/209 (2013.01); A61 K SZOLGALTATO KFT, Budapest (HU) USPC ........... 424/452: 424/400: 514/646; 514/423; 514/342: 514/226.2: 514/534; 514/220; (21) Appl. No.: 13/625,658 514/422; 424/465 (57) ABSTRACT (22) Filed: Sep. 24, 2012 A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodi O O ments include a dosage form that provides therapeutically Related U.S. Application Data effective levels of a first active agent and a second active agent (60) Continuation of application No. 1 1/355,315, filed on in a mammal for an extended period of time following oral Feb. 15, 2006, now Pat. No. 8,329,217, which is a administration. An osmotic device containing a bi-layered continuation-in-part of application No. 1 1/321,736, core is provided. The osmotic device provides a dual con filed on Dec. 29, 2005, now Pat. No. 8,241,667, which trolled release of both drugs from the core. The layers of the is a division of application No. 09/992.488, filed on core are in Stacked, Substantially concentric or Substantially Nov. 6, 2001, now abandoned. eccentric arrangement. Patent Application Publication May 2, 2013 Sheet 1 of 3 US 2013/01 08693 A1 Patent Application Publication May 2, 2013 Sheet 2 of 3 US 2013/01 08693 A1 FIG. 6 Figure 6. Dissolution profile of example 1 8 1O 12 14 16 18 2O 22 24 Time (hrs)-O-Oxybutynin -O-Tolterodine FIG. 7 OO 8 10 12 14 16 18 20 22 24 Time (hrs) -O-Oxybutynin -O-Darifenacin Patent Application Publication May 2, 2013 Sheet 3 of 3 US 2013/01 08693 A1 FIG. 8 1OO - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - O 2 4 6 8 O 12 14 16 18 2O 22 24 Time (hrs) -O-Oxybutynin-O-Darifenacin 60 FIG 11 62 US 2013/01 08693 A1 May 2, 2013 DUAL CONTROLLED RELEASE DOSAGE 0007 U.S. Pat. No. 5,543,155 to Fekete et al. discloses an FORM osmotic device comprising a bi-layered core Surrounded by a semipermeable membrane having two holes (or passage CROSS-REFERENCE TO EARLIER FILED ways). The bi-layered core, however, comprises a first push APPLICATIONS layer containing no drug and a second layer containing drug. The hole(s) can be placed anywhere along the semipermeable 0001. This application claims the benefit of and is continu membrane. This patent does not disclose a core having two ation of U.S. Ser. No. 1 1/355,315, filed Feb. 15, 2006, which different drug-containing layers, each providing a controlled is a continuation-in-part of U.S. application Ser. No. 1 1/321, release of drug through a respective hole in the semiperme 736 filed Dec. 29, 2005, which is a divisional of U.S. appli able membrane. cation Ser. No. 09/992,488 filed Nov. 6, 2001, now aban doned, the entire disclosures of which are hereby 0008 U.S. Pat. No. 4,662.880 to Hamel et al., U.S. Pat. incorporated by reference. No. 4,723,957, U.S. Pat. No. 4,867,969 and U.S. Pat. No. 4,971,790 to Magruder et al. disclose osmotic devices com FIELD OF THE INVENTION prising a single-layered core Surrounded by a semipermeable membrane having two oppositely placed holes. A drug-con 0002 This invention pertains to a dosage form that pro taining coat further Surrounds the semipermeable membrane. vides a controlled release of two different drugs. More par These patents do not disclose a core having two different ticularly, it pertains to a coated dosage form having a bilay drug-containing layers, each providing a controlled release of ered core wherein each layer includes a respective drug that is drug through a respective hole in the semipermeable mem released in a controlled manner. brane. BACKGROUND OF THE INVENTION 0009 U.S. Pat. No. 4,624,847 to Ayer et al. discloses an osmotic device comprising a semipermeable membrane Sur 0003. Osmotic devices and other tablet formulations are rounding a compartment that houses a drug-containing poly known for their ability to provide a controlled release of a mer that increases in size and releases drug. The semiperme wide range of drugs. Such osmotic devices and other tablet able membrane has two oppositely placed holes for releasing formulations are disclosed in U.S. Pat. No. 4,014,334 to drug. This patent does not disclose an osmotic device com Theeuwes et al., U.S. Pat. No. 4,576,604 to Guittard et al., prising core having two different drug-containing layers, Argentina Patent No. 234,493, U.S. Pat. No. 4,673.405 to each providing a controlled release of drug through a respec Guittard et al., U.S. Pat. No. 5,558,879 to Chenet al., U.S. Pat. tive hole in the semipermeable membrane. No. 4,810,502 to Ayeret al., U.S. Pat. No. 4,801.461 to Hamel (0010 U.S. Pat. No. 4,915,954 to Ayer et al. and U.S. Pat. et al., U.S. Pat. No. 5,681,584 to Savastano et al., U.S. Pat. No. No. 4,814,181 to Jordan et al. disclose an osmotic device 3,845,770 and Argentina Patent No. 199,301, the entire dis having a bi-layered core Surrounded by a semipermeable closures of which are hereby incorporated by reference. membrane. The first layer comprises a first drug that is 0004 Osmotic devices have demonstrated utility in deliv released from the core rapidly over a period of 2 minto 2 hr. ering beneficial active agents, such as medicines, nutrients, The second layer comprises a second drug that is released food, pesticides, herbicides, germicides, algaecides, chemi from the core at a controlled rate over a long period of time. cal reagents, and others, to an environment of use in a con The layers of the core are in intimate contact and are not trolled manner over prolonged periods of time. Known separated by another layer, lamina or membrane. The semi devices include tablets, pills, and capsules. permeable membrane can have two holes, one hole adjacent 0005 Advancements in the art have focused on develop each of the two layers of the core such that each layer releases ing osmotic devices with improved semipermeable or porous drug through its own respective hole. The Ayer et al. and membranes, various coatings Surrounding the core and/or the Jordan et al. patents do not disclose an osmotic device having semipermeable membrane, layered osmotically effective a bi-layered core, wherein the layers are in contact with each agents in the core of the device, specific release profiles for other and in laminar arrangement with respect to one another specific active Substances, and specific membrane or core and wherein each layer provides a prolonged and controlled compositions. release of an active agent. 0006 U.S. Pat. No. 4,931,285, U.S. Pat. No. 5,006,346 and U.S. Pat. No. 5,160,743 to Edgren et al., U.S. Pat. No. 0011 U.S. Pat. No. 4,455,143 to Theeuwes et al. discloses 5,160,744, U.S. Pat. No. 5,190,765 and U.S. Pat. No. 5,252, an osmotic device having two compartments defined by a 338 to Jao et al., U.S. Pat. No. 4,612,008, U.S. Pat. No. Surrounding semipermeable membrane and a partition 4,765,989 and U.S. Pat. No. 5,082,668 to Wong et al., U.S. between the compartments. The semipermeable membrane Pat. No. 4,327,725 to Cortese et al., U.S. Pat. No. 5,208,037 has two oppositely placed holes, one for each compartment. to Wright et al., U.S. Pat. No. 4,904,474 to Theeuwes et al. Each compartment contains a drug that is delivered at a con and U.S. Pat. No. 4,627,971 to Ayer disclose osmotic devices trolled rate through a respective hole in the Surrounding mem comprising a bi-layered core Surrounded by a semipermeable brane. The partition is required and retains its integrity during membrane having at least one hole (or passageway). The operation of the osmotic device. bi-layered core, however, comprises a first push-layer con (0012 U.S. Pat. No. 5,866,164 to Kuczynski et al. of Alza taining no drug and a second layer containing drug. The Corporation discloses an osmotic device having a bi-layered hole(s) can be placed anywhere along the semipermeable core Surrounded by a semipermeable membrane. There is no membrane. These patents do not disclose a core having two partition between the layers. The core includes a drug-con different drug-containing layers, each providing a controlled taining layer and a push-layer; and passageways in the Sur release of drug through a respective hole in the semiperme rounding semipermeable membrane only communicate the able membrane. drug-containing layer, and not the push-layer, to the exterior US 2013/01 08693 A1 May 2, 2013 of the device.
Load more

Recommended publications
  • Synthesis and Bioactivity of Analogues of the Marine Antibiotic Tropodithietic Acid
    Synthesis and bioactivity of analogues of the marine antibiotic tropodithietic acid Patrick Rabe1, Tim A. Klapschinski1, Nelson L. Brock1, Christian A. Citron1, Paul D’Alvise2, Lone Gram2 and Jeroen S. Dickschat*1 Letter Open Access Address: Beilstein J. Org. Chem. 2014, 10, 1796–1801. 1Kekulé-Institut für Organische Chemie, Rheinische doi:10.3762/bjoc.10.188 Friedrich-Wilhelms-Universität Bonn, Gerhard-Domagk-Straße 1, 53121 Bonn, Germany and 2Department of Systems Biology, Received: 17 April 2014 Technical University of Denmark, Matematiktorvet bldg. 301, 2800 Accepted: 22 July 2014 Kongens Lyngby, Denmark Published: 06 August 2014 Email: This article is part of the Thematic Series "Natural products in synthesis Jeroen S. Dickschat* - [email protected] and biosynthesis". * Corresponding author Associate Editor: K. N. Ganesh Keywords: © 2014 Rabe et al; licensee Beilstein-Institut. antibiotics; natural products; Roseobacter; SAR study; tropodithietic License and terms: see end of document. acid; tropone Abstract Tropodithietic acid (TDA) is a structurally unique sulfur-containing antibiotic from the Roseobacter clade bacterium Phaeobacter inhibens DSM 17395 and a few other related species. We have synthesised several structural analogues of TDA and used them in bioactivity tests against Staphylococcus aureus and Vibrio anguillarum for a structure–activity relationship (SAR) study, revealing that the sulfur-free analogue of TDA, tropone-2-carboxylic acid, has an antibiotic activity that is even stronger than the bioactivity of the natural product. The synthesis of this compound and of several analogues is presented and the bioactivity of the synthetic compounds is discussed. Introduction Tropodithietic acid (TDA, 1a) is an antibiotic produced by the that are located on a plasmid [6,7], and the adjacent paaZ2 gene marine bacterium Phaeobacter inhibens.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,329,217 B2 Vergezz
    US008329217B2 (12) United States Patent (10) Patent No.: US 8,329,217 B2 VergezZ. et all e 45) Date of Patent:e Dec.e 11, 2012 (54) DUAL CONTROLLED RELEASE DOSAGE 5, 190,765 A 3, 1993 Jao et al. FORM 5,208,037 A 5/1993 Wright et al. 5,252.338 A 10, 1993 Jao et al. 5,399,359 A 3, 1995 Baichwal (75) Inventors: Juan A. Vergez, Buenos Aires (AR): 5,543,155 A 8, 1996 Fekete et al. Marcelo A. Ricci, Buenos Aires (AR) 5,674,895 A 10/1997 Guittard et al. 5,788,987 A 8, 1998 Busetti et al. (73) Assignee: Osmotica Kereskedelmi es Szolgaltato 5,840,754. A 1 1/1998 Guittard et al. Kft, Budapest (HU) 5,866,164 A 2/1999 Kuczynski et al. s 5,912,268 A 6/1999 Guittard et al. 6,106,864 A 8, 2000 Dolan et al. (*) Notice: Subject to any disclaimer, the term of this 6,207,191 B1* 3/2001 Crison et al. .................. 424,472 patent is extended or adjusted under 35 2002/0010216 A1 1/2002 Rogosky et al. U.S.C. 154(b) by 1407 days. 2006/0177510 A1 8/2006 Vergez (21) Appl. No.: 11/355,315 FOREIGN PATENT DOCUMENTS y x- - - 9 JP 2646170 8, 1997 JP 2665858 10, 1997 (22) Filed: Feb. 15, 2006 WO 96.12477 5, 1996 WO 97.18814 5, 1997 (65) Prior Publication Data WO OOf 12069 3, 2000 WO OOf 18997 4/2000 US 2006/0204578 A1 Sep. 14, 2006 WO WOO1/51036 * 7/2OO1 Related U.S.
    [Show full text]
  • Dissertation Enantioselective Β
    DISSERTATION ENANTIOSELECTIVE β-FUNCTIONALIZATION OF ENALS VIA N-HETEROCYCLIC CARBENE CATALYSIS Submitted by Nicholas Andrew White Department of Chemistry In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2015 Doctoral Committee: Advisor: Tomislav Rovis Alan J. Kennan Eugene Y.-X. Chen Robert M. Williams Matt J. Kipper Copyright by Nicholas Andrew White 2015 All Rights Reserved ABSTRACT ENANTIOSELECTIVE β-FUNCTIONALIZATION OF ENALS VIA N-HETEROCYCLIC CARBENE CATALYSIS A series of δ-nitroesters were synthesized through the N-heterocyclic carbene catalyzed coupling of enals and nitroalkenes. The asymmetric coupling of these substrates via the homoenolate pathway afford δ-nitroesters in good yield, diastereoselectivity, and enantioselectivity. This methodology allows for the rapid synthesis of δ-lactams. Using this approach, we synthesized the pharmaceutically relevant piperidines paroxetine and femoxetine. A novel single-electron oxidation pathway for the N-heterocyclic carbene generated Breslow intermediate has been developed. Nitroarenes have been shown to transfer an oxygen from the nitro group to the β-position of an enal in an asymmetric fashion to generate β-hydroxy esters. This reaction affords desired β-hydroxy ester products in good yield and enantioselectivity and tolerates a wide range of enal substrates. A dimerization of aromatic enals to form 3,4-disubstituted cyclopentanones has been investigated. Using a single-electron oxidant, aromatic enals couple to form cyclopenanone products in good yield, good enantioselectivity, and excellent diastereoselectivity. A cross coupling has also been developed to afford non-symmetrical cyclopentanone products. ii ACKNOWLEDGEMENTS First, and foremost, I would like to thank my advisor, Professor Tomislav Rovis for his supervision and guidance over the past five years.
    [Show full text]
  • Resonance Energies of Some Compounds Containing Nitrogen Or Oxygen
    Reprint from Theoret. chim. Ada (Beri.) 17, 235—238 (1970) Springer-Verlag Berlin ■ Heidelberg ■ New York © by Springer- Verlag ■ Printed in Germany Resonance Energies of Some Compounds Containing Nitrogen or Oxygen M ic h a e l J. S. D e w a r and N. T r in a jst io Theoret. chim. Acta(Berl.) 17,235— 238(1970) Resonance Energies of Some Compounds Containing Nitrogen or Oxygen* Michael J. S. Dewar and N. Trinajstić** University of Texas, Department of Chemistry, Austin, Texas 78712, USA Received February 9, 1970 Resonance energies are calculated for a number of aromatic, and potentially aromatic, compounds containing nitrogen or oxygen, using a recent version of our SCF MO n approximation. Recently we reported [1] a variant of our earlier SCF MO n approximation [2—5] in which the one-electron resonance integral (/?£)) is determined from the Mulliken relation instead of the Devvar-Schmeising thermocycle [6, 7]; i.e. fij = K S tj ( 1) where K is a constant characteristic of the atoms i and j. This procedure avoids a difficulty inherent in the earlier treatment, i.e. the need for data concerning “pure” double bonds. Such data are available only for bonds formed by carbon, nitrogen, and oxygen; the thermocycle approach could not therefore be extended to other elements. One important conclusion from the earlier papers was that bonds in classical polyenes [3, 4], and in classical conjugated compounds containing nitrogen or oxygen [8], are localized, in the sense that the calculated heats of atomization can be expressed as sums of “polyene” bond energies that carry over from one molecule to another.
    [Show full text]
  • Synthesis and Bioactivity of Analogues of the Marine Antibiotic Tropodithietic Acid
    Downloaded from orbit.dtu.dk on: Oct 05, 2021 Synthesis and bioactivity of analogues of the marine antibiotic tropodithietic acid Rabe, Patrick; Klapschinski, Tim A.; Brock, Nelson L.; Citron, Christian A.; D'Alvise, Paul; Gram, Lone; Dickschat, Jeroen S. Published in: Beilstein Journal of Organic Chemistry Link to article, DOI: 10.3762/bjoc.10.188 Publication date: 2014 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Rabe, P., Klapschinski, T. A., Brock, N. L., Citron, C. A., D'Alvise, P., Gram, L., & Dickschat, J. S. (2014). Synthesis and bioactivity of analogues of the marine antibiotic tropodithietic acid. Beilstein Journal of Organic Chemistry, 10, 1796-1801. https://doi.org/10.3762/bjoc.10.188 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Synthesis and bioactivity of analogues of the marine antibiotic tropodithietic acid Patrick Rabe1, Tim A.
    [Show full text]
  • Computational Studies of the Tropone Natural Products, Thiotropocin
    Computational Studies of the Tropone Natural SCHEME 1 Products, Thiotropocin, Tropodithietic Acid, and Troposulfenin. Significance of Thiocarbonyl-Enol Tautomerism Edyta M. Greer,†,1 David Aebisher,† Alexander Greer,*,† and Ronald Bentley*,‡ Department of Chemistry and Graduate Center & The City UniVersity of New York (CUNY), Brooklyn College, Brooklyn, New York 11210, and Department of Biological Sciences, UniVersity of Pittsburgh, Pittsburgh, PennsylVania 15260 [email protected]; [email protected] ReceiVed August 22, 2007 viability of 1-3.2-16 To take an example, in 2005, an antibiotic substance was described imprecisely as “the sulfur containing compound thiotropocin or tropodithietic acid produced by Roseobacter strain 27-4...”.10 In 2006, Laatsch16 cited unpub- lished work suggesting that previous structural assignments of 1 and 32-15 were incorrect and that they should instead be 2.16 The X-ray structure has been obtained for 2,8 although Cane provided evidence for the detection of 1 from 13C-labeling 12 experiments in DMSO and CDCl3 solution. One problem is that it is unclear whether 1-3 rearrange with - Computations provide insight to the stability and isomeric each other in solution. Compounds 1 3 can be regarded as possibilities of thiotropocin, tropodithietic acid, and tropo- tautomers and may possess dynamic behavior, possibly influ- enced by solvent proticity and pH. However, no spectroscopic sulfenin. Thiotropocin and tropodithietic acid contain a flat evidence exists for the conjugate base. No previous study 7-membered ring and delocalized π-bonds similar to those + postulated a role of the conjugate base 4 in the equilibration of of tropylium ion (C7H7 ). Troposulfenin is far less stable; it 1-3.
    [Show full text]
  • US 2006/0233859 A1 Whitcup Et Al
    US 20060233859A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0233859 A1 Whitcup et al. (43) Pub. Date: Oct. 19, 2006 (54) METHODS FOR TREATING RETINOPATHY Related U.S. Application Data WITH EXTENDED THERAPEUTIC EFFECT (63) Continuation-in-part of application No. 10/837,357, (75) Inventors: Scott M. Whitcup, Laguna Hills, CA filed on Apr. 30, 2004. (US); David A. Weber, Danville, CA (US) Publication Classification Correspondence Address: (51) Int. Cl. ALLERGAN, INC., LEGAL DEPARTMENT A 6LX 3/573 (2006.01) 2525 DUPONT DRIVE, T2-7H A6F 2/00 (2006.01) IRVINE, CA 92.612-1599 (US) (52) U.S. Cl. ............................................ 424/427: 514/179 (73) Assignee: Allergan, Inc., Irvine, CA (57) ABSTRACT (21) Appl. No.: 11/292,544 Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of (22) Filed: Dec. 2, 2005 a patient at risk of, or Suffering from, the retinopathy. Patent Application Publication Oct. 19, 2006 Sheet 1 of 3 US 2006/0233859 A1 FIGURE 1 Vitreous Humor Concentrations of Dexamethasone in Treated Eye: Comparison of all Dose Levels and Dosage Forms 10000 an(0am-350T OOO - an a 700T 5 100 XC - - - Quantification Limit 0.35OE 10 - a 700E Hours FIGURE 2 Percent of Dexamethasone Released from DEXPS DDS over Time for all Dose Levels and Dosage Forms 60 50 40 - : 30 4 S. 20 10 O Hours Patent Application Publication Oct. 19, 2006 Sheet 2 of 3 US 2006/0233859 A1 FIGURE 3 Vitreous Humor Concentrations of Dexamethasone in Treated Eye: Comparison of all Dose Levels and Dosage Forms - - - Quantification Limit sm 700E Days FIGURE 4 Percent of Dexamethasone Released from DEX PS DDS Over Time for all Dose Levels and Dosage Forms Days Patent Application Publication Oct.
    [Show full text]
  • Stratégies De Synthèse D'un Nouvel Antipsychotique Potentiel
    UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE DES SCIENCES CHIMIQUES Laboratoire d’Innovation Thérapeutique - UMR 7200 THÈSE présentée par : Jessie JOUSSOT soutenue le : 24 Avril 2015 pour obtenir le grade de Docteur de l’université de Strasbourg Discipline / Spécialité : Chimie Organique Stratégies de synthèse d’un nouvel antipsychotique potentiel - Cascades Réactionnelles Palladocatalysées : un outil puissant pour la synthèse de structures polycycliques complexes et hautement fonctionnalisées THÈSE dirigée par : M. SUFFERT Jean Directeur de Recherches au CNRS, université de Strasbourg RAPPORTEURS : M. DAUBAN Philippe Directeur de Recherches au CNRS, Institut de Chimie des Substances Naturelles M. FELPIN François-Xavier Professeur des universités, université de Nantes AUTRES MEMBRES DU JURY : M. COMPAIN Philippe Professeur des universités, université de Strasbourg Mme BLOND Gaëlle Chargée de Recherches au CNRS, université de Strasbourg M. NICOLAS Marc Ingénieur, laboratoires Pierre Fabre UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE DES SCIENCES CHIMIQUES Laboratoire d’Innovation Thérapeutique - UMR 7200 THÈSE présentée par : Jessie JOUSSOT soutenue le : 24 Avril 2015 pour obtenir le grade de Docteur de l’université de Strasbourg Discipline / Spécialité : Chimie Organique Stratégies de synthèse d’un nouvel antipsychotique potentiel - Cascades Réactionnelles Palladocatalysées : un outil puissant pour la synthèse de structures polycycliques complexes et hautement fonctionnalisées THÈSE dirigée par : M. SUFFERT Jean Directeur de Recherches au CNRS, université de Strasbourg RAPPORTEURS : M. DAUBAN Philippe Directeur de Recherches au CNRS, Institut de Chimie des Substances Naturelles M. FELPIN François-Xavier Professeur des universités, université de Nantes AUTRES MEMBRES DU JURY : M. COMPAIN Philippe Professeur des universités, université de Strasbourg Mme BLOND Gaëlle Chargée de Recherches au CNRS, université de Strasbourg M.
    [Show full text]
  • Tropone-Substituted Phenyloxazolidinone
    Europaisches Patentamt (19) European Patent Office Office europeenpeen des brevets EP 0 673 370 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) intci.e: C07D 263/20, A61K 31/42 of the grant of the patent: 07.01.1998 Bulletin 1998/02 (86) International application number: PCT/US93/09589 (21) Application number: 93923304.5 (87) International publication number: (22) Date of filing: 14.10.1993 WO 94/13649 (23.06.1994 Gazette 1994/14) (54) TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS DURCH EINE TROPON GRUPPE SUBSTITUIERTE PHENYLOXAZOLIDINONE-DERIVATE ALS ANTIBAKTERIELLES MITTEL AGENTS ANTIBACTERIENS A BASE DE PHENYLOXAZOLIDINONE SUBSTITUEE PAR TROPONE (84) Designated Contracting States: (74) Representative: Perry, Robert Edward et al AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL GILL JENNINGS & EVERY PT SE Broadgate House 7 Eldon Street (30) Priority: 08.12.1992 US 988589 London EC2M 7LH (GB) 13.01.1993 US 3778 21.05.1993 US 66356 (56) References cited: EP-A-0 127 902 EP-A- 0 316 594 (43) Date of publication of application: DE-A-3 149 608 27.09.1995 Bulletin 1995/39 • BULLETIN OF THE CHEMICAL SOCIETY OF (73) Proprietor: PHARMACIA & UPJOHN COMPANY JAPAN, vol. 62, no. 1 , January 1989 , TOKYO, Kalamazoo, Michigan 49001 (US) JP; pages 128 - 142, TETSUO NOZOE ET AL.: 'Synthesis and reactions of (72) Inventor: BARBACHYN, Michael, Robert 2-arylhydrazinotropones II Synthesis of 5-aryl Kalamazoo, Ml 49001 (US) tropolones and B-ring-open colchicine analogues via benzidine type rearrangement of 2-(2-arylhydrazino)tropones' DO o Is- CO CO Is- CO Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice the Patent Office of the Notice of shall be filed in o to European opposition to European patent granted.
    [Show full text]
  • Functional Heptagon-Centred Polyaromatics
    Durham E-Theses Functional Heptagon-Centred Polyaromatics TURLEY, ANDREW,THOMAS How to cite: TURLEY, ANDREW,THOMAS (2020) Functional Heptagon-Centred Polyaromatics, Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/13533/ Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in Durham E-Theses • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders. Please consult the full Durham E-Theses policy for further details. Academic Support Oce, Durham University, University Oce, Old Elvet, Durham DH1 3HP e-mail: [email protected] Tel: +44 0191 334 6107 http://etheses.dur.ac.uk Functional Heptagon-Centred Polyaromatics Andrew Thomas Turley A Thesis Submitted for the Degree of Doctor of Philosophy January 2020 Dedicated to my loving Friends and Family ii Table of Contents Abstract ...................................................................................................................... vii Declaration ............................................................................................................... viii Conferences Attended and Presentations Given ........................................................
    [Show full text]
  • M. Sc. II, Sem.-III & IV ORGANIC CHEMISTRY SYLLABUS
    SOLAPUR UNIVERSITY, SOLAPUR SCHOOL OF CHEMICAL SCIENCES M. Sc. II, Sem.-III & IV ORGANIC CHEMISTRY SYLLABUS (Choice Based Credit System-CBCS) (w.e.f. June, 2016) - 1 - SOLAPUR UNIVERSITY, SOLAPUR M. Sc. II, ORGANIC CHEMISTRY COURSE SYLLABUS CHOICE BASED CREDIT SYSTEM (CBCS) (w.e.f. June 2016) A two-year duration M. Sc. Organic Chemistry course syllabus has been prepared as per the CBCS semester system. M. Sc. II, SEM-III & SEM-IV Organic Chemistry syllabus will be implemented from June 2016. The syllabus has been prepared taking into consideration the syllabi of other Universities, SET, NET, UGC guidelines, and the specific inputs of the Expert Committee Members from Pune University, Pune, Shivaji University Kolhapur and Dr. BAMU, Aurangabad. General Structure of the Course: The course will be of four semesters spread over two academic years. Each semester will have four theory papers of 70 marks for university external examination and 30 marks for internal examination of each semester and two practical’s of 70 marks, 30 marks for internal practical of each semester. The distribution of marks is mentioned below Theory Paper (Semester exam), 16 X 70+30 marks 1600 marks Practicals (semester end exam.), 8 X 70+30 marks 800 marks Tutorials for each semester, 4 X 25 100 marks Total: 2500 marks Ratio of marks (Theory: Practical): (73:27) Paper Credit Semester Title of the Paper Semester exam L T P Code s I Hard core Theory IA Total HCT-101 Inorganic Chemistry -I 70 30 100 4 - 4 HCT-102 Organic Chemistry -I 70 30 100 4 - 4 HCT-103 Physical Chemistry
    [Show full text]
  • Synthesis of Six-Membered Rings and Inhibitors of Protein Kinases
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Helsingin yliopiston digitaalinen arkisto Division of Pharmaceutical Chemistry Faculty of Pharmacy University of Helsinki Finland Synthesis of Six-Membered Rings and Inhibitors of Protein Kinases Alexandros Kiriazis ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Pharmacy of the University of Helsinki, for public examination in lecture room 1041, Viikki Biocenter 2 (Viikinkari 5), on 14 September 2012, at 12 noon. Helsinki 2012 1 Supervised by Professor Jari Yli-Kauhaluoma, PhD Division of Pharmaceutical Chemistry Faculty of Pharmacy University of Helsinki Helsinki, Finland Reviewed by Professor Tarek Ghaddar, PhD Department of Chemistry American University of Beirut Beirut, Lebanon Professor Angel Messeguer, PhD Department of Chemical and Biomolecular Nanotechnology The Institute for Advanced Chemistry of Catalonia Consejo Superior de Investigaciones Científicas (CSIC) Barcelona, Spain Opponent Professor Peter Goekjian, PhD Lab. Chimie Organique 2-Glycosciences Université de Lyon, France © Alexandros Kiriazis 2012 ISBN 978-952-10-8192-7 (paperback) ISBN 978-952-10-8193-4 (PDF) ISSN 1799-7372 http://ethesis.helsinki.fi Helsinki University Print Helsinki 2012 2 Abstract The six-membered rings have a priviledged presence in both natural products and synthetic compounds such as drug molecules. Multiple methods to prepare them in the laboratory have been developed. The Diels-Alder reaction provides several pathways toward the construction of substituted six-membered rings with a high degree of regio-, diastereo- and enantioselectivity. It can be considered to be the most important and powerful carbon- carbon bond-forming reaction of all, in synthetic organic chemistry.
    [Show full text]